Nizatidine

Summary

Nizatidine (CHEMBL3183075) is an approved small-molecule anti-ulcer drug (ATC A02BA04); indicated across 7 conditions including peptic ulcer disease and gastroesophageal reflux disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A02BA04
• Indications: 7 conditions
• Clinical trials: 7
• Chemistry: 331.5 Da · C12H21N5O2S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3183075
Name	Nizatidine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4513
ChEBI	CHEBI:7601
ATC	A02BA04
Molecular formula	C12H21N5O2S2
Molecular weight	331.5
InChIKey	SGXXNSQHWDMGGP-UHFFFAOYSA-N

SMILES: CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C

IUPAC name: 1-N’-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine

ChEBI definition: A member of the class of 1,3-thiazoles having a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl moiety at position 4.

Pharmacological roles (ChEBI): anti-ulcer drug, H2-receptor antagonist, cholinergic drug.

Also known as: Acinon, Axid, Axid ar, LY 139037, LY-139037, Nizatidina, Nizatidine, NSC-759289, Zinga 150, Zinga 300, NIZATIDINE, SID11112849

Patent coverage: 3,629 distinct patent families (13,993 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Acetylcholinesterase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ACHE	5.25	IC50	5615	nM	CHEMBL_ACT_7714336

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
peptic ulcer disease	4	MONDO:0004247	HP:0004398
gastroesophageal reflux disease	4	MONDO:0007186	EFO:0003948
duodenal ulcer	4	MONDO:0005412	EFO:0004607
esophagitis	4	MONDO:0001409	HP:0100633
gastritis	1	MONDO:0004966	EFO:0000217
gastroparesis	1	MONDO:0006769	EFO:1000948

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE1	4
PHASE4	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00486005	PHASE4	COMPLETED	Weight Gain Management in Patients With Schizophrenia
NCT00373334	PHASE3	COMPLETED	Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)
NCT01161927	PHASE1	COMPLETED	Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy’s Laboratories Limited Under Non- Fasting Conditions
NCT01161940	PHASE1	COMPLETED	Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy’s Laboratories Limited Under Fasting Conditions
NCT01409395	PHASE1	COMPLETED	Drug-Drug Interaction Study With Metformin and Nizatidine
NCT02232308	PHASE1	COMPLETED	Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects
NCT02555852	Not specified	COMPLETED	Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).